Skip to main content
padlock icon - secure page this page is secure

Homozygous FCGR3A‐158V alleles predispose to late onset neutropenia after CHOP‐R for diffuse large B‐cell lymphoma

Buy Article:

$52.00 + tax (Refund Policy)


Recent reports suggest genetic polymorphisms influence susceptibility to rituximab‐induced late‐onset neutropenia (LON), which in turn may be a predictor of good outcome in B‐cell lymphoma.

We report the largest study to date assessing FCGR3AV158F polymorphisms in diffuse large B‐cell lymphoma (DLBCL) treated with cyclophosphamide/hydroxydaunorubicin/Oncovin (vincristine)/prednisone/rituximab (CHOPR). The influence of C1qAA276G polymorphisms in DLBCL, and the impact of both polymorphisms on susceptibility to LON and outcome were also examined.

115 DLBCL patients treated with CHOP‐R were compared with 105 healthy White people controls with regards to FCGR3AV158F and C1qAA276G polymorphisms. LON incidence and event‐free and overall survival (EFS and OS) were analysed for linkage to either polymorphism.

The FCGR3AV158F but not the C1qAA276G polymorphism influenced the risk of developing LON. 50% of FCGR3A‐158V/V patients experienced LON. In contrast, only 7% V/F and 2% F/F experienced LON. The FCGR3A‐158V/V genotype was associated with LON compared with V/F (P = 0.028) and F/F genotypes (P = 0.005). Although no patients with either LON or FCGR3A‐158V homozygosity relapsed compared with 33% FCGR3A‐158F/F and 21% non‐LON, this did not translate into improved EFS or OS.

Polymorphic analysis may be a predictive tool to identify those at high risk of LON. Prospective studies are required to establish definitively if LON or FCGR3A‐158V/V genotype influences outcome.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Document Type: Research Article

Publication date: October 1, 2012

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more